Phaseline

Companies › Alesta Therapeutics

Alesta Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ALE1
alkaline phosphatase replacement
–Phase 1Hypophosphatasia (HPP)Jan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07179640ALE1Phase 1Hypophosphatasia (HPP)Metabolic and endocrineJan 2027

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.